Try our beta test site
9 studies found for:    aplidine
Show Display Options
Rank Status Study
1 Terminated Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
Condition: Relapsed/Refractory Leukemia
Intervention: Drug: Plitidepsin plus Cytarabine
2 Terminated Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
Condition: Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma
Intervention: Drug: plitidepsin
3 Completed Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
Conditions: Advanced Solid Tumors;   Lymphomas
Interventions: Drug: Plitidepsin and Sorafenib;   Drug: Gemcitabine and Plitidepsin
4 Recruiting Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Plitidepsin;   Drug: Bortezomib;   Drug: Dexamethasone
5 Active, not recruiting Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Condition: Relapsed/Refractory Multiple Myeloma
Interventions: Drug: plitidepsin + dexamethasone;   Drug: dexamethasone
6 Completed Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Condition: Myelofibrosis
Intervention: Drug: APLIDIN (plitidepsin)
7 Terminated A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: Aplidin (plitidepsin)
8 Completed
Has Results
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Plitidepsin
9 Completed Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Drug: Aplidin®

Study has passed its completion date and status has not been verified in more than two years.